Immuneering CorporationIMRXNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank50
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-2.81
↑ 67% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-8.58
Historical baseline
PeriodValueYoY Change
2025-2.81-426.4%
2024-0.53+79.9%
2023-2.65-126.7%
2022-1.17+88.9%
2021-10.56+10.8%
2020-11.83+61.2%
2019-30.50-